Table 1. Baseline patient characteristicsa.
| Characteristic | Value |
|---|---|
| Baseline screening | |
| Total evaluable | 92 |
| Age (years) | 63 (24–83) |
| Sex (male/female) | 51 (55)/41 (45) |
| Body surface area (m2) | 1.95 (1.40–2.72) |
| ECOG performance status | 1 (0–1) |
| Primary tumor site | |
| Breast | 25 (27) |
| Prostate | 24 (26) |
| Lung | 11 (12) |
| Head and neck | 7 (8) |
| Other | 25 (27) |
| Pretherapy chemistry and hematology | |
| Total bilirubin (× ULN) | 0.42 (0.17–1.25) |
| Aspartate aminotransferase (× ULN) | 0.78 (0.30–4.70) |
| Alanine aminotransferase (× ULN) | 0.60 (0.10–6.61) |
| Alkaline phosphatase (× ULN) | 0.82 (0.39–8.69) |
| α1-Acid glycoprotein (mg/dl) | 126 (60–257) |
| Erythromycin breath test C20 (%dose/min) | 0.047 (0.0015–0.124) |
ECOG, Eastern Cooperative Oncology Group; N/A, not available; ULN, upper limit of institutional normal.
a
Continuous data are given as median with range in parentheses, and categorical data as number of patients with percentage of the total population in parentheses.